Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study

BackgroundMET amplification or METex14 skipping mutations are uncommon oncogenic events in NSCLC patients. Clinicopathological characteristics, concurrent gene alterations, and prognosis of MET TKIs in these patients are yet to be elucidated.MethodsWe retrospectively analyzed the genomic profiles of...

Full description

Bibliographic Details
Main Authors: Li Liu, Farhin Shaheed Kalyani, Haiyan Yang, Chunhua Zhou, Yi Xiong, Songlin Zhu, Nong Yang, Jingjing Qu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Oncology
Subjects:
concurrent genomic alterations
MET inhibitor
MET amplification
MET exon 14 skipping mutation
non-small cell lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.649766/full

Similar Items

Similar Items